Latest News

Both the Vanguard Energy ETF and the Vanguard FTSE Pacific ETF are beating the S&P 500 and the Nasdaq-100 this year, but the paths to near-term upside may be bumpy.

SanDisk and Micron have both been AI memory superstars in 2026, but one of them still looks underappreciated relative to its growth.

The Oracle of Omaha’s under-the-radar portfolio has over $149 million put to work in two index funds that consistently print profits for long-term investors.

Tesla is gearing up to report its Q3 results later this month following the recent publication of better-than-expected delivery numbers.

The S&P 500 experienced a historic breadth divergence. It's possible that it doesn't end soon.

Micron and Sandisk shares could decline sharply as the memory chip supply shortage is resolved.

Locking in a high yield with Treasury bonds is becoming increasingly appealing.

Buffett thinks many stocks are too hot to touch right now, but these three aren't.

ServiceTitan (NASDAQ:TTAN) unveiled an AI-focused product strategy at its Pantheon 2026 event, introducing “Max,” which Chief Executive Officer and Co-Founder Ara Mahdessian described as a self-running, self-improving version of a contracting business. Mahdessian framed the company’s AI strategy as

Hormel Foods stock is definitely out of favor, but it's a rebound candidate with a tasty dividend.

Retirees should still receive a decent-sized benefits boost.

These five consumer stocks have all doubled their dividend payouts since 2019, and each has a fresh reason to believe the growth isn't finished.

Money market fund investors are telling a chilling tale of what may come for a historically expensive stock market.

These growing businesses are trading at reasonable valuations.

Micron’s revenue soared in the triple digits in the quarter.

They may offer us important clues about what’s next for AI.

The top of the chipmaker's latest target is around 11 times its sales from last fiscal year. How much of this is already in the share price?

Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The company is developing the regimen in endometrial cancer and hormone receptor-positive, HER2-negative

The streaming video leader is now in a more mature phase of its lifecycle.